<DOC>
	<DOCNO>NCT00359359</DOCNO>
	<brief_summary>The purpose study determine whether study drug ZK 219477 ( also know SH Y03757A ) combine cisplatin , effective treatment small cell lung cancer patient receive prior treatment lung cancer</brief_summary>
	<brief_title>A Study New Chemotherapy Agent Combination With Cisplatin Treat Small Cell Lung Cancer</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer Schering Pharma AG , Germany.Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Small Cell</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Smallcell lung cancer Stage extensive disease Adequate function major organ system Use highly effective birth control method female childbearing potential Prior chemotherapy smallcell lung cancer Prior surgical resection radiotherapy SCLC within least 3 4 week prior inclusion exception radiation brain metastasis Superior vena cava syndrome obstruction vital structure Untreated malignant hypercalcemia ; Extensive disease amenable radiation therapy ; Symptomatic brain metastasis require wholebrain irradiation Known allergy hypersensitivity platinumcontaining drug Pregnancy breastfeeding Use investigational drug within 4 week start study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Small Cell Lung Cancer</keyword>
</DOC>